BiPASSNCT07052214
PSMA PET Combined With MRI for the Detection of PCa
StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 10 words
- Enrollment closed, study ongoing
- Site details revised at 18 of 18 sites
Notable Primary completion pushed from Jun 2026 to Jan 2027v3 Show 5 more changesShow less
- Enrollment increased: 204 → 338 participants
- Eligibility criteria shortened, about 143 words
- Trial sites expanded: 1 → 18 locations
- Study completion pushed from Nov 2026 to Apr 2027
- Study description expanded, about 6 words
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jul 2025 to Aug 18, 2025
- Collaborators expanded, about 3 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Primary Objective
Timeframe: 12 months
Co-Primary Endpoint
Timeframe: 12 months
Arms and interventions
Illuccix: 68Ga-PSMA-11/Gallium Ga 68 GozetotideOther
This is a single arm study. All participants will first undergo mpMRI and PSMA PET scans (one single IV bolus of Gallium Ga 68 Gozetotide administered)
Drugs: 68Ga-PSMA-11
Sites
18 sites in 2 countries
United States 16, Australia 2